Loading...
Loading...
AEZS| Name | Value |
|---|---|
| Revenues | 4.0K |
| Cost of Revenue | 59.7K |
| Gross Profit | -55.7K |
| Operating Expense | 6,027.0K |
| Operating I/L | -6,082.7K |
| Other Income/Expense | 356.4K |
| Interest Income | 285.0K |
| Pretax | -5,726.3K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -5,726.3K |
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing therapeutics and diagnostic tests. The company's lead product, macimorelin, is marketed under the Macrilen brand name and is used for the diagnosis of adult and childhood-onset growth hormone deficiency, as well as oncology indications. Aeterna Zentaris Inc. also has license agreements for the development and commercialization of macimorelin in the United States and Canada, as well as for the research, development, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Additionally, the company is engaged in research and development for potential COVID-19 vaccines and treatments for neuromyelitis optica spectrum disorder and Parkinson's disease.
